CClinicalTrials.gg
CompletedNCT00399633Updated May 14, 2008

Neuropeptides in the Humane Intra- og Extracerebral Circulation.

An interventional study of sumatriptan in Healthy and Migraine, sponsored by Danish Headache Center. Completed at 1 site in Denmark. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2008-05-14.

Sponsored by Danish Headache Center · Not applicable and Interventional

Phase
Not applicable
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The study aim at examining whether Sumatriptan changes the plasma values of the neuropeptides vasoactive intestinal polypeptide (VIP), calcitonin gene-related peptide (CGRP) and pituitary adenylate cyclase activating peptide (PACAP) and the prostanoids 6-keto-PGF1α, and PGE2, PGD2 og PGF2α.

Read the detailed description

The study is meant to give a better understanding of the basic mechanisms behind migraine, and a better understanding of the effects of sumatriptan on the trigemino vascular system.

The endpoints are changes in the plasma values of the neuropeptides vasoactive intestinal polypeptide (VIP), calcitonin gene-related peptide (CGRP) and pituitary adenylate cyclase activating peptide (PACAP) and the prostanoids 6-keto-PGF1α, and PGE2, PGD2 og PGF2α.

02

Conditions studied

  • Healthy
  • Migraine

Keywords

  • VIP
  • PACAP
  • CGRP
  • Prostanoids
03

In context

Lead sponsor

Danish Headache Center is the lead sponsor of 125 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • healthy volunteers
  • 18-50 years,
  • 50-100 kg.
  • Fertile women must use birth control.

Exclusion criteria

Exclusion Criteria:

  • All primary types of headache
  • Daily intake of medicine except birth control
  • Pregnancy
  • Hypertension
  • Hypotension
  • other chronic disease
05

Study design

Phase
Not applicable
Allocation
Non-randomized
Intervention model
Single group
Masking
Single
Enrollment
16 participants (actual)

Interventions

  • Drugsumatriptan
06

What researchers measure

Primary outcomes

  1. Blood concentration of vasoactive intestinal polypeptide (VIP),

  2. calcitonin gene-related protein (CGRP), pituitary adenylate cyclase

  3. activating peptide (PACAP,) and the prostanoids

  4. 6-keto-PGF1α, PGE2, PGD2 and PGF2α, sampled from different

  5. venous catheters.

07

Study locations

1 site
  • Danish Headache Center
    Glostrup, Copenhagen, Copenhagen 2600, Denmark
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 14, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00399633
Lead sponsor
Danish Headache Center
Collaborators
Glostrup University Hospital, Copenhagen, Bispebjerg Hospital
First posted
Nov 15, 2006
Start date
Jan 2007
Primary completion
Apr 2007
Completion
Apr 2007
Last update
May 14, 2008

Study contacts

Jakob Møller Hansen, MD
principal investigator · Danish Headache Center
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion